Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | TDO2 | P48775 | 1/20 | 0.50 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7716671 | 0.85 | CTSD (0.51) | CTSDRAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL13294935 | 0.84 | HDAC7 (0.53) | CTSDRAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL1003770 | 0.84 | PLK1 (0.54) | CTSDRAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL5679153 | 0.83 | ALDH1A1 (0.67) | CTSDRAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL966735 | 0.83 | CTSD (0.62) | CTSDNPC1MAPTALDH1A1KDM4E | |
| SCHEMBL4939202 | 0.83 | TP53 (0.66) | CTSDRAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL4338973 | 0.81 | CTSD (0.60) | CTSDRAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL4338344 | 0.81 | CTSD (0.65) | CTSDRAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL4345662 | 0.81 | KDM4E (0.62) | CTSDMAPTALDH1A1HPGDKDM4E | |
| SCHEMBL23716794 | 0.81 | CTSD (0.63) | CTSDRAB9ANPC1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3116502-A1 | METHODS AND COMPOSITIONS FOR INHIBITING RHO/MRTF-MEDIATED DISEASES AND CONDITIONS | The Regents Of The University Of Michigan (US) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015138326-A1 | METHODS AND COMPOSITIONS FOR INHIBITING RHO/MRTF-MEDIATED DISEASES AND CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015138326-A1 | METHODS AND COMPOSITIONS FOR INHIBITING RHO/MRTF-MEDIATED DISEASES AND CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-09-17 | — | — | WO | disclosed |
| US-20150250769-A1 | METHODS AND COMPOSITIONS FOR INHIBITING RHO/MRTF-MEDIATED DISEASES AND CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2015-09-10 | — | — | US | disclosed |
| US-20150250769-A1 | METHODS AND COMPOSITIONS FOR INHIBITING RHO/MRTF-MEDIATED DISEASES AND CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2015-09-10 | — | — | US | disclosed |
| US-20150250769-A1 | METHODS AND COMPOSITIONS FOR INHIBITING RHO/MRTF-MEDIATED DISEASES AND CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2015-09-10 | — | — | US | disclosed |
| WO-2009094205-A2 | 3-ARYL-6-ARYL-7H-[1,2,4]TRIAZOLO[3,4-B][1,3,4]THIADIAZINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250769-A1 | METHODS AND COMPOSITIONS FOR INHIBITING RHO/MRTF-MEDIATED DISEASES AND CONDITIONS | RHOA, ARHGEF1, ARHGEF2 | CTSD 2731/4885RAB9A 309/4885NPC1 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.